Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website


Insmed reported $13.83M in Cost of Sales for its fiscal quarter ending in March of 2023.

Cost Of Sales Change
Alimera Sciences ALIM:US USD 2.03M 97K
BioMarin Pharmaceutical BMRN:US USD 126.55M 741K
Dynavax Technologies DVAX:US USD 14.71M 62.78M
Gilead Sciences GILD:US USD 1.4B 5M
Heron Therapeutics HRTX:US USD 16.85M 4.23M
Insmed INSM:US USD 13.83M 761K
Mirati Therapeutics MRTX:US 817K 217K
Novartis NVS:US USD 3.83B 8M
Regeneron Pharmaceuticals REGN:US USD 457.5M 83.1M
Sarepta Therapeutics SRPT:US USD 35.02M 4.22M
Seattle Genetics SGEN:US USD 111.78M 3.57M
Ultragenyx Pharmaceutical RARE:US USD 12.26M 6.94M
Vertex Pharmaceuticals VRTX:US USD 266.9M 16.4M